Previous 10 | Next 10 |
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium PR Newswire Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis PLEASANTON, Calif. ...
10x Genomics (NASDAQ:TXG) stock dropped to a near 3-week low on Wednesday after Goldman Sachs slashed its price target to $85 from $95, but maintained its Neutral rating. The new PT implies 18.9% upside to TXG's last close. Wall Street analysts on average rated TXG Buy, with an average PT of ...
April showers came early for biotech investors, leaving the SPDR S&P Biotech ETF (NYSEMKT: XBI) down over 17% year to date, trailing the S&P 500 . The good news is that solid companies are on sale. 10x Genomics (NASDAQ: TXG) and Guardant Health (NASDAQ: GH)...
10x Genomics to Report First Quarter Financial Results on May 4, 2022 PR Newswire PLEASANTON, Calif. , April 7, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close ...
The growth selloff continues to persist and with the Ukraine war raging, persistent inflation and rate hikes on the horizon, it makes sense that high multiple growth is largely out of favor. If you were going to sell your growth positions, specifically in mid and small cap names, I wo...
The bloodbath for Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) continues, despite the fund being up slightly on Thursday. Wood’s ETF is -36% YTD and is currently working towards its fifth straight downward month. Meanwhile, this week has been particularly difficult...
The Ark Innovation ETF was fallen 60% from its high water mark, far more than 10%ish drop of the handful of growth stocks which top the S&P 500 and NASDAQ100. Charts and tables for price and AUM show clearly the the majority of investors in ARKK bought at the top; most ARKK holder...
FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...
10x Genomics to Present at the Cowen 42nd Annual Health Care Conference PR Newswire PLEASANTON, Calif. , March 1, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced t...
10X Genomics (NASDAQ:TXG) was added as a new short idea at Hedgeye, which sees a deceleration in NIH funding in terms of new funded scientists, a key input for Hedgeye's revenue forecast. Growth peaked in 2020 in rate of change terms, but has been decelerating, according to Hedgeye analy...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...